Cisplatin (Platinol ®)
Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma
Cancer Medicine 2022 August 28 [Link] Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. Methods: Transcriptomic data, clinical information,…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…
Read MoreOrganic extract of Geodia cydonium induces cell cycle block in human mesothelioma cells
Oncology Letters 2022 June 28 [Link] Francesco Di Meo, Roberta Esposito, Rossana Cuciniello, Gregorio Favale, Mario Arenga, Nadia Ruocco, Genoveffa Nuzzo, Angelo Fontana, Stefania Filosa, Stefania Crispi, Maria Costantini Abstract The serious side effects caused by chemotherapeutics and the development of cancer chemoresistance represent the most significant limitations in the treatment of cancer. Some alternative…
Read MorePrognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients
World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…
Read MoreTen-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Langenbeck’s Archives of Surgery 2022 June 23 [Link] Miklos Acs, Michael Gerken, Ivana Gajic, Max Mayr, Jozef Zustin, Pompiliu Piso Abstract Purpose: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). Methods: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four…
Read MoreBAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study
Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…
Read MoreSystemic treatment in patients with malignant pleural mesothelioma – real life experience
BMC Cancer 2022 April 20 [Link] Barbara Ziółkowska, Bożena Cybulska-Stopa, Dimitrios Papantoniou, Rafał Suwiński Abstract Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is a standard first-line therapy for malignant pleural mesothelioma. Despite some progress, almost all MPM patients…
Read MoreMinimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials
Lung Cancer 2022 March 29 [Link] Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, Corneel Coens, Madeleine T King, Mirjam A G Sprangers, Mogens Groenvold, Kim Cocks, Galina Velikova, Hans-Henning Flechtner, Andrew Bottomley Abstract Objectives: A minimally important difference (MID) is the smallest difference in quality of life (QoL) perceived as relevant by patients or clinicians.…
Read MoreAnetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
The Lancet Oncology 2022 April [Link] Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein Jr, Jonathan…
Read MoreComparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
JAMA Network Open 2022 March 1 [Link] Tomer Meirson, Francesca Pentimalli, Francesco Cerza, Giovanni Baglio, Steven G Gray, Pierpaolo Correale, Marija Krstic-Demonacos, Gal Markel, Antonio Giordano, David Bomze, Luciano Mutti Abstract Importance: Some recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their impact on quality of life and overall survival…
Read More